Stryker Spine Looks To Correct Domestic Posture With Scannell Appointment
This article was originally published in The Gray Sheet
Executive Summary
The new head of Stryker's spine business will face the challenge of accelerating U.S. sales growth for the segment with minimal assistance from the firm's OP-1 bone morphogenic protein
You may also be interested in...
AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria
CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application
AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria
CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application
Stryker BMP Putty Receives HDE Approval For Spine Applications
Stryker will extend its OP-1 bone morphogenic protein into the revision spine surgery market following recent humanitarian device exemption clearance of a putty form, the firm announced April 8